Bristol-Myers Squibb cefadroxil patent
Executive Summary
Was infringed by Moleculon's Kalipharma unit, the New Jersey Federal Court rules June 15. The drug accounted for about one-fourth of Kalipharma's sales revenue, before the firm suspended its sale in May following an International Trade Commission decision barring import of the drug. Moleculon said it will appeal the patent decision. Zenith and Biocraft recently reached a settlement of regarding a similar patent suit brought by Bristol-Myers Squibb ("The Pink Sheet" April 2, T&G-12).